RECOMBINATE 500 IU

Land: Israel

Språk: engelska

Källa: Ministry of Health

Aktiva substanser:

COAGULATION FACTOR VIII RECOMBINANT 500 IU/VIAL

Tillgänglig från:

TEVA MEDICAL MARKETING LTD.

ATC-kod:

B02BD05

Läkemedelsform:

POWDER FOR SOLUTION FOR INJECTION

Administreringssätt:

I.V

Tillverkad av:

BAXTER S.A., BELGIUM

Terapeutisk grupp:

COAGULATION FACTOR VII

Terapeutiska indikationer:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Tillstånd datum:

2010-07-01